We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.
- Authors
Miller, Antonia G; Tan, Genevieve; Binger, Katrina J; Pickering, Raelene J; Thomas, Merlin C; Nagaraj, Ram H; Cooper, Mark E; Wilkinson-Berka, Jennifer L
- Abstract
Advanced glycation end products (AGEs) and the renin-angiotensin system (RAS) are both implicated in the development of diabetic retinopathy. How these pathways interact to promote retinal vasculopathy is not fully understood. Glyoxalase-I (GLO-I) is an enzyme critical for the detoxification of AGEs and retinal vascular cell survival. We hypothesized that, in retina, angiotensin II (Ang II) downregulates GLO-I, which leads to an increase in methylglyoxal-AGE formation. The angiotensin type 1 receptor blocker, candesartan, rectifies this imbalance and protects against retinal vasculopathy.
- Publication
Diabetes, 2010, Vol 59, Issue 12, p3208
- ISSN
1939-327X
- Publication type
Journal Article
- DOI
10.2337/db10-0552